Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02236611 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT02236611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02236611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel-group, Open-label Study to Evaluate the Efficacy and Safety of Umeclidinium (UMEC) 62.5 mcg Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Lead sponsor
GlaxoSmithKline
Phase
Phase 4
Overall status
Completed
Start date
September 26, 2014
Completion date
June 2, 2015
Enrollment
1,036 (actual)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary disease, chronic obstructive